WO2025233366 - THERAPEUTIC AND DIAGNOSTIC APPLICATIONS OF ELONGATION OF VERY LONG CHAIN FATTY ACIDS PROTEIN 1
National phase entry is expected:
Publication Number
WO/2025/233366
Publication Date
13.11.2025
International Application No.
PCT/EP2025/062403
International Filing Date
06.05.2025
Title **
[English]
THERAPEUTIC AND DIAGNOSTIC APPLICATIONS OF ELONGATION OF VERY LONG CHAIN FATTY ACIDS PROTEIN 1
[French]
APPLICATIONS THÉRAPEUTIQUES ET DIAGNOSTIQUES D'ALLONGEMENT DE LA PROTÉINE 1 D'ACIDES GRAS À TRÈS LONGUE CHAÎNE
Applicants **
VIB VZW
KATHOLIEKE UNIVERSITEIT LEUVEN
Inventors
MAZZONE, Massimiliano
PRETTO, Samantha
Priority Data
24174500.9
07.05.2024
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2262 | |
| EPO | Filing, Examination, Granting | 9174 | |
| Japan | Filing, Examination, Granting | 2124 | |
| South Korea | Filing, Examination, Granting | 2009 | |
| USA | Filing, Examination, Granting | 7140 |
Total:
22,709
Contact Us
Abstract[English]
The invention relates to modulation of the function or expression of Elongation of very long chain fatty acids protein 1 (ELOVL1) and its therapeutic applications. In particular, CD8+ T cells lacking or substantially lacking functional ELOVL1 are envisaged, and adoptive transfer of such CD8+ T cells is useful in the treatment of cancer. Furthermore, ELOVL1 expression in CD8+ T cells is a biomarker for response to cancer therapy including an immune checkpoint inhibitor.[French]
L'invention concerne la modulation de la fonction ou de l'expression de l'allongement de la protéine 1 d'acides gras à très longue chaîne (ELOVL1) et ses applications thérapeutiques. En particulier, des lymphocytes T CD8+ dépourvus ou sensiblement dépourvus de ELOVL1 fonctionnelle sont envisagés, et le transfert adoptif de tels lymphocytes T CD8+ est utile dans le traitement du cancer. En outre, l'expression de ELOVL1 dans les lymphocytes T CD8+ est un biomarqueur pour la réponse à une thérapie anticancéreuse comprenant un inhibiteur de point de contrôle immunitaire.